Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2006
11/23/2006US20060264492 methyl [5(6)-(4-alanylaminophenylthio)-1H-benzimidazol-2yl]carbamate; for treating neovascularization, solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis
11/23/2006US20060264479 Nicotinamide Derivatives Useful as p38 Inhibitors
11/23/2006US20060264452 Analgesics; immunomodulators and for treatment of drug dependence; for example, 5'-Bromo-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5 alpha -epoxypyrido[2',3':6,7]morphinan
11/23/2006US20060264436 Method of Treating a Psychotic Disorder
11/23/2006US20060264434 Chemokine receptor binding heterocyclic compounds
11/23/2006US20060264432 Adenosine A1, A2a, and A2b receptor ligands; coupling the 2-mercapto-3,5-dicyano-4-aryl-6-aminopyridine to a substituted alkyl or alkenyl compound; antiischemic agents; cardiovascular disorders
11/23/2006US20060264417 N-(3-tetrahydrobenzodiazepinonyl)succamides: 2R,3S)N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; inhibit production of A beta -peptide, preventing neurological amyloid deposits; Alzheimer's disease
11/23/2006US20060264397 Compositions and methods for targeting cancer cells
11/23/2006US20060264390 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
11/23/2006US20060264389 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
11/23/2006US20060264378 Cxcr4 antagonist and use thereof
11/23/2006US20060263881 Methods of expanding and selecting disease associated T-Cells
11/23/2006US20060263854 Immunodiagnostic assays using reducing agents
11/23/2006US20060263852 Asp2
11/23/2006US20060263849 The analogs are resistant to diaminopeptidase IV degradation and bind zinc; are active over an extended time in vivo
11/23/2006US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006US20060263392 Method for treating neovascularization
11/23/2006US20060263388 Injectable or oral administration of a drug with an active ingredient of an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus; side effect reduction
11/23/2006DE60202452C5 Pyridazinonaldose reductase inhibitoren Reductase inhibitors Pyridazinonaldose
11/23/2006CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006CA2608957A1 Pyrrolidine derivative or salt thereof
11/23/2006CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature
11/22/2006EP1724349A1 TIE Ligand Homologues
11/22/2006EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006EP1724283A2 Corticotropin releasing factor receptor 2 agonists
11/22/2006EP1724279A2 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia.
11/22/2006EP1724278A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
11/22/2006EP1724271A1 Preventive and/or therapeutic agent for neutrophilic inflammation disease
11/22/2006EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/22/2006EP1724267A1 Pyrimidine derivative
11/22/2006EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006EP1724263A1 Basic amine compound and use thereof
11/22/2006EP1724262A1 1-(2h)-isoquinolone derivative
11/22/2006EP1724258A1 Heteroarylphenylurea derivative
11/22/2006EP1724257A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
11/22/2006EP1723970A1 Medicinal composition containing cxcr3 inhibitor
11/22/2006EP1723959A1 Composition comprising platelet-rich plasma
11/22/2006EP1723953A1 Nutritional supplements
11/22/2006EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006EP1723854A1 Beverage or drug containing bamboo extract as main ingredient
11/22/2006EP1722766A2 Management of ophthalmologic disorders, including macular degeneration
11/22/2006EP1551860B1 Glucocorticoid receptor ligands for the treatment of metabolic disorders
11/22/2006EP1534265B1 Combination of an aromatase inhibitor with a bisphosphonate
11/22/2006EP1483265B1 Purine derivatives as kinase inhibitors
11/22/2006EP1480620B1 (ester)-lysolecithins in liposomes
11/22/2006EP1467982B1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
11/22/2006EP1461034B1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines
11/22/2006EP1458683B1 Heteroaryl-substituted aminocyclohexane derivatives
11/22/2006EP1438055A4 D-tagatose as an anti-biofilm agent
11/22/2006EP1438049B1 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
11/22/2006EP1427717B1 Bioprecursors for percutaneous application
11/22/2006EP1423131B1 Calcium trifluoroacetate with cytotoxic activity
11/22/2006EP1407261A4 In vivo bioreactors
11/22/2006EP1401413B1 Use of tyrosine kinase inhibitions for treating allergic diseases
11/22/2006EP1399156B1 Alkylidene pirazolidinedione derivatives and their use for treating diabetes and obesity
11/22/2006EP1390360B1 Crystalline form of omeprazole
11/22/2006EP1370575B1 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
11/22/2006EP1351933B1 Il-8 receptor antagonists
11/22/2006EP1317450B1 Pyrazole compounds useful as protein kinase inhibitors
11/22/2006EP1312364B1 Gatifloxacin as cytokine production inhibitor
11/22/2006EP1301487B1 Viral polymerase inhibitors
11/22/2006EP1301475B1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
11/22/2006EP1294757B1 Glucagon-like peptide-1 analogs
11/22/2006EP1268435B1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity
11/22/2006EP1268412B1 Sulphonamido-substituted bridged bicycloalkyl derivatives
11/22/2006EP1244651B1 Diamidine compounds as dna minor groove binders
11/22/2006EP1220682B1 Stabilized liquid polypeptide-containing pharmaceutical compositions
11/22/2006EP1146899B1 Methods of using neurotrophin 3 (nt-3) for the treatment of gastrointestinal hypomotility disorders
11/22/2006EP1120114B1 Compositions and methods for treating conditions responsive to estrogen
11/22/2006EP1078054B1 Monomeric mp52/gdf-5 with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone
11/22/2006EP1066247B1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
11/22/2006EP1051176B1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/22/2006EP1037603B1 Membrane virus host range mutations and their uses as vaccine substrates
11/22/2006EP0970104B1 Steroid sulfamates, method for the production and use thereof
11/22/2006EP0942925B1 Inhibitors of interleukin-1 beta converting enzyme
11/22/2006EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase
11/22/2006CN1867560A 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
11/22/2006CN1867552A Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
11/22/2006CN1867547A Compounds having crth2 antagonist activity
11/22/2006CN1867339A Novel use of cannabinoid receptor agonist
11/22/2006CN1864741A 'Huo Xiang Zheng Qi' essence powder for poultry and livestock, its preparation process and application method
11/22/2006CN1864696A New formulation
11/22/2006CN1864693A A glycerin and fructose injection and preparation method thereof
11/22/2006CN1864677A An anti-thrombus anti-restenosis composite medicine coated on eluting stent
11/22/2006CN1864543A A nutrition food for postponing human senescence
11/22/2006CN1864534A Pure natural health noodle with astragalus root and asiabell root
11/22/2006CN1285594C Oxytocin agonists
11/22/2006CN1285591C Dimeric compounds and their use as anti-viral agents
11/22/2006CN1285588C Farnesyl protein transferase inhibitors
11/22/2006CN1285578C Substituted benzoic acid amides and use for inhibition of angiogenesis thereof
11/21/2006US7138543 Thiolalkyl benzoic acid derivatives
11/21/2006US7138533 acetylcholinesterase inhibitory action and an alpha 1 antagonistic action
11/21/2006US7138531 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
11/21/2006US7138530 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
11/21/2006US7138524 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
11/21/2006US7138492 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
11/21/2006US7138432 Arylsulfonamido-substituted hydroxamic acid derivatives
11/21/2006US7138430 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/21/2006US7138428 Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same
11/21/2006US7138427 Cognition activators